Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2009

01-12-2009 | Short communication

Who would have thought a single Ki67 measurement would predict long-term outcome?

Authors: Mitch Dowsett, Roger A'Hern, Janine Salter, Lila Zabaglo, Ian E Smith

Published in: Breast Cancer Research | Special Issue 3/2009

Login to get access

Excerpt

Recent data from neoadjuvant studies, predominantly for endocrine therapy but also for chemotherapy, indicate that a single measurement of the nuclear proliferation marker Ki67 made in the breast carcinoma during/after neoadjuvant therapy is strongly predictive of long-term disease outcome. In an era when many mega-parameter signatures have been derived with the aim of improving the accuracy of prediction, it is superficially very surprising that a single immunohistochemical measurement can act in this fashion. This provokes a number of questions, and the following three are addressed below: What is the underlying reason for this predictive ability? Given that Ki67 is influenced by treatment/external factors and is not stable in the short term, why does it predict in the long term? What is the best time for measuring Ki67? …
Literature
1.
Zabaglo L, Salter J, Anderson H, Hills M, A'Hern R, Dowsett M: Comparative validation of the SP6 and MIB1 antibodies to Ki67 and their use in tissue microarray (TMA) and image analysis for breast cancer. San Antonio Breast Cancer Symposium; 9-13 December San Antonio, Texas, USA. Abstracts will be published as a supplement to Cancer Research. 2009, AACR, Philadelphia
2.
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005, 11 (2 Pt 2): 951s-958s.PubMed
3.
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007, 99: 167-170. 10.1093/jnci/djk020.CrossRefPubMed
4.
Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003, 63: 6523-6531.PubMed
5.
Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M: The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009, 116: 53-68. 10.1007/s10549-008-0081-7.CrossRefPubMed
6.
Urruticoechea A, Smith IE, Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005, 23: 7212-7220. 10.1200/JCO.2005.07.501.CrossRefPubMed
7.
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008, 14: 5158-5165. 10.1158/1078-0432.CCR-07-4756.CrossRefPubMed
8.
Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.CrossRef
9.
Dowsett M, Cuzick J, Ingle JN, Coates A, Forbes JF, Bliss JM, Buyse M, Baum M, Buzdar AU, Colleoni M, Coombes C, Snowdon C, Gnant MFX, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R: Meta-analyses of breast cancer outcomes in adjuvant trials of aromatase ihibitors versus tamoxifen. J Clin Onco. 2009.
Metadata
Title
Who would have thought a single Ki67 measurement would predict long-term outcome?
Authors
Mitch Dowsett
Roger A'Hern
Janine Salter
Lila Zabaglo
Ian E Smith
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 3/2009
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2434

Other articles of this Special Issue 3/2009

Breast Cancer Research 3/2009 Go to the issue

Section introduction

Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8

Section introduction

Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6

Short communication

Next-generation sequencing

Short communication

Are current drug development programmes realising the full potential of new agents? The scenario

Short communication

Gene expression profiling of breast cancer

Short communication

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits